Value
6.3/10data confidence 67%| Component | Sub-score |
|---|---|
| P/S | 8.6 |
| EV/EBITDA | 4.3 |
| p ocf | 7.7 |
| Analyst target | 6.0 |
- ▸P/OCF: 12.7x (FFO proxy — REITs gated off P/E)
MPT · Why this verdict
Why Medical Properties Trust (MPT) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.7/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Despite reporting a GAAP net loss, the company generates a free cash flow margin of 71% and a free cash flow yield of 26.8%, indicating that real economic value is being produced at a rate that the income statement does not capture. Quality breakdown | Free cash flow yield remains above 15% over the next 4 quarters, confirming that cash generation capacity is durable even as GAAP earnings remain negative. | →Stable |
| CounterA GAAP net loss combined with 30% short interest suggests that sophisticated investors have concluded the GAAP loss reflects real economic deterioration, not merely accounting timing differences. | ||
Short interest stands at 30% of the float and has been flagged as justified by the scoring model, meaning the market is pricing in a material probability of further financial deterioration beyond what the current stock price reflects. Risk breakdown | Short interest declines below 20% of float over the next 6 months as the company demonstrates sustained positive free cash flow, reducing the fundamental basis for short positioning. | →Stable |
| CounterA 30% short interest level that is characterized as justified suggests a meaningful cohort of professional investors have done detailed analysis and concluded the risk is underpriced. | ||
With a debt-to-equity ratio of 2.1x generating a leverage penalty, and 2 of the last 4 quarters producing earnings misses including a negative 642% and negative 1,077% surprise, the company's financial structure amplifies downside risk if operating conditions deteriorate. Earnings | Earnings results in the next 2 quarters avoid misses exceeding 50%, showing that the extreme variance in reported results is stabilizing. | →Stable |
| CounterREIT earnings inherently involve large non-cash depreciation charges and asset impairments that distort earnings per share; cash-based metrics like price-to-adjusted-funds-from-operations may tell a more favorable story. | ||
The current price of $4.88 sits only 3.1% below the analyst take-profit target of $5.03, an asymmetry ratio of only 0.63x versus a 1.5x minimum bar, and the downside scenario to the stop-loss at $4.70 is larger than the upside, creating an unfavorable risk profile at current entry. Targets | The stock price reaches $5.25 within 6 months as free cash flow improvement drives a re-rating, creating at least a 7% reward-to-risk ratio above the current take-profit. | →Stable |
| CounterNear-zero upside to the analyst target in a high-leverage, high-short-interest REIT with recent earnings misses suggests the stock is fairly valued to overvalued at current levels. | ||
Despite reporting a GAAP net loss, the company generates a free cash flow margin of 71% and a free cash flow yield of 26.8%, indicating that real economic value is being produced at a rate that the income statement does not capture.
→StableQuality breakdown
- Expectation
- Free cash flow yield remains above 15% over the next 4 quarters, confirming that cash generation capacity is durable even as GAAP earnings remain negative.
CounterA GAAP net loss combined with 30% short interest suggests that sophisticated investors have concluded the GAAP loss reflects real economic deterioration, not merely accounting timing differences.
Short interest stands at 30% of the float and has been flagged as justified by the scoring model, meaning the market is pricing in a material probability of further financial deterioration beyond what the current stock price reflects.
→StableRisk breakdown
- Expectation
- Short interest declines below 20% of float over the next 6 months as the company demonstrates sustained positive free cash flow, reducing the fundamental basis for short positioning.
CounterA 30% short interest level that is characterized as justified suggests a meaningful cohort of professional investors have done detailed analysis and concluded the risk is underpriced.
With a debt-to-equity ratio of 2.1x generating a leverage penalty, and 2 of the last 4 quarters producing earnings misses including a negative 642% and negative 1,077% surprise, the company's financial structure amplifies downside risk if operating conditions deteriorate.
→StableEarnings
- Expectation
- Earnings results in the next 2 quarters avoid misses exceeding 50%, showing that the extreme variance in reported results is stabilizing.
CounterREIT earnings inherently involve large non-cash depreciation charges and asset impairments that distort earnings per share; cash-based metrics like price-to-adjusted-funds-from-operations may tell a more favorable story.
The current price of $4.88 sits only 3.1% below the analyst take-profit target of $5.03, an asymmetry ratio of only 0.63x versus a 1.5x minimum bar, and the downside scenario to the stop-loss at $4.70 is larger than the upside, creating an unfavorable risk profile at current entry.
→StableTargets
- Expectation
- The stock price reaches $5.25 within 6 months as free cash flow improvement drives a re-rating, creating at least a 7% reward-to-risk ratio above the current take-profit.
CounterNear-zero upside to the analyst target in a high-leverage, high-short-interest REIT with recent earnings misses suggests the stock is fairly valued to overvalued at current levels.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Medical Properties Trust generates free cash flow equal to 71% of revenue despite a GAAP net loss, and its Rule of 40 score of 84 is elite, but 30% short interest, consecutive earnings misses, and leverage of 2.1x debt-to-equity create a high-risk setup with minimal upside margin.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
5.8/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 1.9 |
| Gross margin | 10.0 |
| Op margin | 10.0 |
| Net margin | 0.0 |
| Current ratio | 4.5 |
| FCF quality | 10.0 |
| Moat | 5.8 |
| Rule of 40 | 9.5 |
| Piotroski F | 6.7 |
- ▸FCF-positive despite GAAP loss (FCF margin 71%, FCF yield 28.5%)
- ▸Rule of 40: 84 (elite)
Growth
7.8/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 5.6 |
| EPS growth | 10.0 |
Momentum
4.5/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.5 |
| MACD | 6.1 |
| OBV | 10.0 |
| MA position | 2.2 |
| Volume | 0.7 |
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA but MA still rising (+2.2%/30d) — pullback in uptrend, not confirmed weakness
Sentiment
6.0/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 8.1 |
| erm sentiment | 5.0 |
- ▸Analyst upside: 24%
Insider
5.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.1 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
5.5/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 8.8 |
| quality rank | 1.9 |
| growth rank | 6.3 |
Technical
5.4/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 6.3 |
| support resistance | 5.7 |
| 52w position | 4.7 |
| gap | 5.0 |
Risk (lower is worse)
3.9/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 0.6 |
| days to cover | 0.0 |
| volatility | 4.4 |
| put call | 10.0 |
| implied vol | 4.1 |
| beta | 5.1 |
| debt equity | 2.9 |
- ▸High short interest justified: 29%
- ▸Concentration risks: 2 MED (10-K Item 1A)
Catalyst
2.9/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 1.1 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
| dividend safety | 3.5 |
- ▸Earnings concerns: 1B/2M
- ▸Yield trap warning: high yield but unsafe
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (7)
- MOMENTUM:4.5>=4.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:26d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:1.3<1.5@spot
Warning (1)
- MOMENTUM:4.5<5.5 (soft — BUY_NOW allowed but watch)
Reward-to-Risk
1.27
Upside
+8.3%
Downside
6.5%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilityAggressive — Beta 1.46>1.3, MCap $2.7B<$5B
Investment implication
The F-path SELL output reflects an overall score of 4.2 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Growth at 7.8) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( ASYMMETRY:1.3<1.5@spot) reinforce the read. Current asymmetry R:R is 1.27 — supplementary context, not the trigger for this path.
The strongest dimensions are Growth at 7.8, Value at 6.3, and Sentiment at 6.0; the weakest are Catalyst at 2.9, Risk (lower is worse) at 3.9, and Momentum at 4.5. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of 1.27 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Fcf Positive Despite Gaap Loss
Trip ifFree cash flow yield falls below 10% or free cash flow turns negative for 2 consecutive quarters.
- P2High Short Interest Justified
Trip ifShort interest rises above 35% of float, indicating increased conviction among short sellers beyond the current justified level.
- P3Leverage Earnings Miss Pattern
Trip ifEarnings miss exceeds 100% for 2 consecutive quarters, or debt-to-equity ratio rises above 3.0x.
- P4Minimal Price Upside
Trip ifThe stock price falls below $4.50, representing more than 7% downside from current levels, triggering the stop-loss threshold.